Genesis Biomed Plans to Increase its Revenue by 33% in 2023

Genesis Biomed, the Spanish consultancy specializing in the biomedical sector expects to conclude the 2023 financial year with a 33% increase in its turnover, to reach €2 million, according to Natalia de la Figuera, director of operations and managing partner of Genesis Biomed.

De la Figuera also commented that Genesis Biomed has opened a new office in Valencia, on Calle Travesía, settling in the BioHub, a space for companies in the biomedical sector that is located in the Valencia Marina.

Genesis Biomed pointed to the “potential of the ecosystem of the Valencian Community in the biomedical sector” and for this reason, it takes a leap and adds a third location to its locations in Barcelona and Madrid, according to the consultant’s operations director.

If you want to find more details about Genesis Biomed and to read the most important financial news of the day, download for free our companion app Born2Invest.

Genesis Biomed has offices in Barcelona, ​​Madrid, and Valencia

The manager helps newly created companies, spin-offs, entrepreneurs, and research centers in the field of biomedicine and health sciences and offers them advisory services, both in the development of their business plan and in the process of fundraising and negotiation with family offices, business angels and other venture capital agents.

Genesis Biomed’s position in Valencia is backed by its experience in the field of technology transfer and early-stage biomedical projects in the region, having worked for universities (UPV, UV, UMH), hospitals, and healthcare environment (IIS La Fe, Incliva, Isabial or Fisabio), start-ups such as Corify, Arthex, Sonda and Doppli and institutions such as Inndromeda, among others.

Likewise, Genesis Biomed has become a partner in Bioval, the association of companies and entities in the sector that includes biotechnology, biomedicine, and bioeconomy, and which constitutes the cluster of the Valencian Community.

Genesis Biomed has constituted, since its foundation in 2017, two investment vehicles

Genesis Biomed was created in 2017 in Catalonia by Josep Lluís Falcó, founder and CEO of the consultancy, and De la Figuera, opening an office in the Barcelona Science Park (PCB). In 2019, the company opened a new office on Calle Velázquez in Madrid.

Since its incorporation, Genesis Biomed has set up two investment vehicles. The first is Genesis Ventures, currently in the process of divestment, which was born with an endowment of 2.5 million euros and with a focus on biopharmaceuticals, biotechnology, medical devices, in vitro diagnostics, and digital health. Genesis Ventures has promoted more than ten companies and has collaborated in almost twenty financing rounds.

In 2022, Genesis Biomed launched its second investment vehicle, Genesis Tech Transfer Boost, backed by FI Group and Crowd4Ventures, with an investment goal of €1 million over the next four years.

Last June, Genesis Tech Transfer Boost made its first investment of 25,000 euros in the biotechnological Spinally Medical, a biotechnological company that has devised and protected a spinal cord stimulation system for the treatment of disabling low back pain, much smaller and more efficient than current cables of neuromodulation.

This low back pain is one of the leading causes of disability worldwide. Currently, more than eighty million people in the United States and Europe suffer from disabling low back pain (LBP). The investment made by Genesis Tech Transfer Boost will make it possible to advance in the development of the product, achieving a degree of maturity that allows the attraction of venture capital investment in future rounds, facilitating its clinical validation and its arrival on the market.

__

(Featured image by Myriams-Fotos via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.